In 2015, the US FDA Approved the Use of Secukinumab

question 4

Multiple Choice

In 2015, the US FDA approved the use of secukinumab for the treatment of psoriasis, a disease caused by chronic inflammation in the skin. Secukinumab is fully human monoclonal antibody against IL-17A. Clinical trials of this treatment indicated an increased rate of infections in patients on secukinumab, the majority of which were upper respiratory tract infections caused by viral or bacterial pathogens. For many of these infections, this side effect of secukinumab can be explained by:

• A) Poor recruitment of neutrophils to infected airways
• B) Lack of mucus production by airway epithelial cells
• C) Poor recruitment of eosinophils to infected airways
• D) Enhanced production of antimicrobial peptides by airway epithelial cells
• E) Loss of tight junctions between airway epithelial cells

---

Definitions:

Risk Takers

Individuals or entities that are willing to undertake actions with uncertain outcomes, potentially leading to significant rewards or failure.

High Degrees

Advanced levels of academic achievement, typically referring to graduate-level education such as master's or doctoral degrees.

Entrepreneurs

Individuals who initiate, manage, and assume the risks of a business venture in pursuit of profit and innovation.

Technopreneur

An entrepreneur who focuses on innovation in technology, leveraging technological advancements to develop new products or services.